A Massachusetts-based wound care and sports medicine company announced plans recently for a new biomanufacturing facility in Smithfield. Regenerative medicine company Organogenesis is investing roughly $100 million to build the facility off Technology Way, with plans to add more than 200 full-time jobs.
The 122,000 square-foot site will house manufacturing, laboratory, warehouse, and distribution operations to support the company’s “advanced wound care” products, including future expansions. It will also be equipped to resume production of Dermagraft, an FDA-approved product used to treat diabetic foot ulcers, according to Organogenesis.
CEO and Board Chair Gary S. Gillheeney Sr. called the project a vital aspect of the company’s commitment to growing its presence in New England. He said their vision for the facility is to “be a catalyst” for the life sciences industry in Rhode Island and to foster “continued regional cooperation in biotechnology.”
“This state-of-the-art facility will allow us to remain on the leading edge of advancements in regenerative medicine with added capacity to expand upon our multiple technology platforms and bring new innovations to patients, enabling our growth plans for many years to come,” Gillheeney said.
Mark Turco, president and CEO of the Rhode Island Life Science Hub, expects the multi-year investment in Smithfield to create high-quality jobs and help solidify the state’s reputation as a leader in life sciences.